Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 28, 2009

Omeros Achieves $3.1M Milestone under a Schizophrenia Partnership with The Stanley Medical Research Institute

  • Omeros was awarded $3.1 million in a second tranche of equity and grant funding from The Stanley Medical Research Institute (SMRI) to support late-stage preclinical development of its schizophrenia drug candidates. The funds serve as a milestone payment to Omeros for having successfully met preclinical compound optimization criteria.

    Omeros' schizophrenia product candidates inhibit the phosphodiesterase 10 (PDE10) enzyme. “We believe that our program could provide product candidates that have benefits not offered by existing antipsychotics and we are working to advance into clinical trials next year,” says Gregory A. Demopulos, M.D., chairman and CEO.

    In December 2006, Omeros entered into an agreement with SMRI to develop its PDE10 inhibitors through Phase I trials. The $2.6 million first tranche of grant and equity funding was received at signing of the deal, and Omeros stands to earn another $3.3 million.

    ---

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »